Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics

Core Insights - NovoCure reported revenue of $167.2 million for the quarter ended September 2025, reflecting a year-over-year increase of 7.8% and a positive surprise of 5.76% over the Zacks Consensus Estimate of $158.1 million [1] - The company's EPS was -$0.33, which is a decline from -$0.28 in the same quarter last year, but it exceeded the consensus estimate of -$0.42 by 21.43% [1] Financial Performance - The revenue growth of 7.8% indicates a solid performance compared to the previous year [1] - The EPS surprise of +21.43% suggests better-than-expected performance in terms of profitability [1] Geographic Revenue Breakdown - Revenue from Greater China was $5.6 million, surpassing the average estimate of $3.65 million [4] - Revenue from Japan reached $9.39 million, slightly above the average estimate of $9.12 million [4] - Revenue from the United States was $96.61 million, exceeding the average estimate of $95.13 million [4] Stock Performance - NovoCure's shares have returned -3.6% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]